Search peptides, terms, sources/
Growth hormone axis

AOD-9604

Also known as: hGH Fragment 176-191 · hGH Fragment 177-191 · Tyr-hGH

Growth hormone fragment studied for weight management. Not licensed in the UK; its largest human trial showed no significant weight-loss benefit.

UK status checked . Evidence last reviewed . By the PeptGuru editorial team (Astute Management).

UK status
Not licensed in the UKChecked

Evidence grade: best single recorded finding

How grading works

Best recorded finding: Moderate evidence (level 3 of 4 on our scale)

This grades the evidence behind one recorded finding. It does not rate the compound.

1 finding at this grade. See all findings

These labels summarise the recorded evidence and the UK regulatory position. They are not recommendations. None of them means a product is safe to obtain or use, and none of them means a product is licensed or lawful to supply. AOD-9604 is recorded as not licensed in the UK (checked 14 November 2026).

Best study type
Human trials2 human trials · 2 animal studies

What is AOD-9604?

AOD-9604 is a synthetic fragment of human growth hormone, studied for weight management in animal and human studies. It is not licensed in the UK, and the best-powered human trial, a randomised placebo-controlled study reported only as a conference record, did not show a significant weight-loss benefit on its primary endpoint.

It is a 16-amino-acid fragment from the C-terminal end of growth hormone, with an added tyrosine. It was designed to keep growth hormone's reported fat-metabolising (lipolytic) activity without activating the growth-hormone receptor or the IGF-1 axis. It was tested in six human clinical trials, and its developer discontinued it after the main trial did not meet its primary endpoint.

Class
Growth hormone fragment (lipolytic peptide)
Origin
Fragment / derived
UK status
Not licensed in the UK
Best study type
Human trials
Evidence last reviewed

How does AOD-9604 work?

AOD-9604 is a piece of human growth hormone that kept the fat-releasing effect in cell and animal studies without the full hormone's other effects. It did not raise IGF-1 in human trials. In the largest human trial, this plausible mechanism did not turn into a significant weight-loss effect.

The mechanism in more detail

Foundational pharmacology work reported that AOD-9604 retains the lipolytic, or fat-releasing, activity of full-length human growth hormone in isolated rat adipocytes, without the anti-lipogenic and diabetogenic signalling associated with the complete hormone. In chronic-treatment studies in obese mice, AOD-9604 reduced fat mass and retained partial lipolytic activity even in mice lacking beta3-adrenergic receptors, suggesting its mechanism is not wholly dependent on that receptor pathway. Across the human trials reviewed, AOD-9604 did not raise IGF-1 levels, distinguishing its reported mechanism of action from growth-hormone-receptor-mediated pathways and from the growth-promoting effects of full-length GH.

This mechanistic profile did not translate into confirmed clinical benefit. The programme’s largest and most rigorous trial, a 24-week, randomised, double-blind, placebo-controlled study (534 enrolled, 502 randomised), did not show a statistically significant fat-loss effect versus placebo at its primary endpoint. AOD-9604 is best understood as a case in which a plausible, well-characterised biological mechanism did not translate into demonstrated clinical efficacy in the best-powered trial conducted. A full peer-reviewed publication of that pivotal trial’s results has not been identified.

Across the six-trial human programme (893 participants pooled), no elevation of IGF-1, no glucose intolerance or insulin resistance, and no antibody formation against AOD-9604 were reported, a consistent tolerability signal confined to short and medium trial durations rather than long-term use.

Mechanisms and targets

Lipid/fat metabolism modulationLipolysis stimulationBeta3-adrenergic-receptor-linked lipolytic signalling (implicated, not GH receptor)

Classification and structure

Names
AOD-9604; hGH Fragment 176-191; hGH Fragment 177-191 (older nomenclature used in the original preclinical papers); Tyr-hGH(177-191)
Class
Growth hormone fragment (lipolytic peptide)
Origin
Fragment / derived
Structure
A 16-amino-acid fragment corresponding to the C-terminal region of human growth hormone (historically numbered aa 176-191 or 177-191 depending on the numbering convention used), with an N-terminal tyrosine addition. AOD stands for anti-obesity drug.
Routes used in the research
Oral, intravenous and subcutaneous routes were used across the six human trials, depending on trial phase. Preclinical work used subcutaneous and intraperitoneal injection in rodents.How the substance was given in the studies cited on this page. This describes study methods only. It is not guidance on use.

What does the research show?

AOD-9604 has 4 recorded research findings. Each shows how strong it is, the kind of study behind it, its source and its main limitation.

Findings by strength of evidence

4 findings

Counts recorded findings by grade. It does not rate the compound.

Findings by strength of evidence
PreliminaryLimitedModerateStrongNot graded
03100

Rat adipocyte lipolysis Limited

AOD-9604 retained the lipolytic (fat-releasing) activity of full-length hGH in isolated rat adipocytes without the associated anti-lipogenic/diabetogenic signalling of the full hormone.

Study type
Animal
Population
Isolated rat adipocytes
Source
1 Heffernan et al., 2001

Limitation: Single study; mechanistic and in-vitro only.

Obese and knockout mice Limited

Chronic AOD-9604 treatment reduced fat mass in obese mice and retained partial lipolytic activity even in beta3-adrenergic-receptor knockout mice, distinguishing its mechanism from a purely beta3-AR-dependent pathway.

Study type
Animal
Population
Obese mice; beta3-AR knockout mice
Source
2 Heffernan et al., 2001

Limitation: Same research group and programme as the mechanistic study above; no controlled human data match this comparison; not replicated by an outside laboratory.

The OPTIONS Phase IIb trial Limited No effect shown

The pivotal, larger Phase IIb trial (534 obese adults enrolled and 502 randomised, 24 weeks, randomised, double-blind, placebo-controlled, the "OPTIONS" study) did not demonstrate a statistically significant fat-loss effect of AOD-9604 versus placebo at its primary endpoint.

Study type
Human trial
Population
534 enrolled and 502 randomised obese adults, 24 weeks
Source
3 Dominikowski et al., 2026

Limitation: This is the single most important finding for this peptide and it is a negative result from the best-powered trial in the programme.

Limitations in full

This is the single most important finding for this peptide and it is a negative result from the best-powered trial in the programme. A peer-reviewed publication of this trial has not been identified. The results were presented at a 2005 conference (Herd et al., Obesity Research, conference proceedings). A 2026 review (Dominikowski et al., Frontiers in Endocrinology) reports that the trial did not show a significant benefit on its primary weight-loss endpoint, and describes the evidence as based mainly on sponsor-reported phase 2 programme outcomes.

Six pooled Phase I/II trials Moderate

Across six randomised, double-blind, placebo-controlled Phase I/II trials (893 participants total), AOD-9604 showed no elevation of IGF-1, no glucose intolerance/insulin resistance signal, no anti-AOD-9604 antibody formation, and no serious treatment-related adverse events, a safety profile the authors describe as indistinguishable from placebo.

Study type
Human trial
Population
893 participants across 6 trials
Source
4 Stier et al., 2013

Limitation: Primarily a safety/tolerability finding rather than an efficacy finding; the summarising publication was authored with apparent sponsor/manufacturer involvement (Metabolic Pharmaceuticals-linked development programme), a conflict-of-interest factor that belongs in the record even though it does not disqualify the finding.

What safety findings have been reported?

2 safety findings are recorded for AOD-9604. A short list does not mean a substance is safe; it reflects what has been studied and reported.

No IGF-1 or antibody signal

No IGF-1 elevation, no glucose intolerance, no insulin resistance, and no anti-AOD-9604 antibody formation were observed across six Phase I/II human trials (n=893).

Source
4 Stier et al., 2013

Adverse-event reporting

893 people took part in the six randomised trials of AOD-9604. No serious adverse events or treatment-related withdrawals were reported. The trials were too small and too short to rule out rarer harms.

Source
4 Stier et al., 2013

What is AOD-9604's UK regulatory status?

Marketing authorisation
None. AOD-9604 never received a marketing authorisation from the MHRA, the FDA, the EMA, or (based on the sources reviewed) Australia's TGA; clinical development was discontinued by the sponsor (Metabolic Pharmaceuticals Ltd) around 2007 following the Phase IIb trial's failure to meet its primary efficacy endpoint. A check of the MHRA Products database active substance index on 14 November 2026 found no entry for AOD-9604.
Prescription status
Not applicable; no licensed UK product was found to classify.
Medicine class
Would meet the Human Medicines Regulations 2012 (SI 2012/1916), Regulation 2 definition of a "medicinal product" if administered or marketed with a view to a pharmacological or physiological effect, an unlicensed medicinal product in that context.
MHRA position
Unlicensed medicinal product if supplied or marketed for human administration with a weight-loss or therapeutic purpose.
Authorised use
None, anywhere, at any point in its development history. Unlike several other peptides in this catalogue that hold licensed status elsewhere even where unlicensed in the UK, AOD-9604 was never licensed by any regulator worldwide; its discontinuation was a genuine efficacy failure, not a market-access or geography story.
Other restrictions
None identified beyond the standard unlicensed-medicine enforcement framework. In sport, the WADA 2026 Prohibited List (in force from 1 January 2026) names AOD-9604 under S2.2.3, growth hormone fragments.

These labels summarise the recorded evidence and the UK regulatory position. They are not recommendations. None of them means a product is safe to obtain or use, and none of them means a product is licensed or lawful to supply. AOD-9604 is recorded as not licensed in the UK (checked 14 November 2026).

References

5 sources, numbered as cited above. Each has its own page with its limitations and everything that cites it.

  1. Heffernan MA, Ng FM, Ho KKY (2001). The lipolytic action of human growth hormone fragment 177-191 in isolated rat adipocytes. Endocrinology, 142(2):626-632Animal-preclinical, In-vitro · Original ↗
  2. Heffernan M, Summers RJ, Thorburn A, Ogru E, Gianello R, Jiang WJ, Ng FM (2001). The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta3-AR knock-out mice. Endocrinology, 142(12):5182-5189Animal-preclinical · Original ↗
  3. Dominikowski A, Rękoś Z, Olejarz M, Szczepanek-Parulska E, Domin R, Ruchała M (2026). The emerging landscape of performance-enhancing peptides modulating the GH-IGF1 axis. Frontiers in EndocrinologyDOI 10.3389/fendo.2026.1822475 · PMID 42395176 · Original ↗
  4. Stier H, Vos E, Kenley D (2013). Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans. Journal of Endocrinology and Metabolism, 3(1-2):7-15Human clinical trial, RCT · DOI 10.4021/jem157w · Original ↗
  5. Medicines and Healthcare products Regulatory Agency (MHRA) (2026). MHRA Products database: active substance index (A to Z), checked 14 November 2026. MHRA Products database · Original ↗

Questions about AOD-9604

What is AOD-9604?

AOD-9604 is a synthetic fragment of human growth hormone, studied for weight management in animal and human studies. It is not licensed in the UK, and the best-powered human trial, a randomised placebo-controlled study reported only as a conference record, did not show a significant weight-loss benefit on its primary endpoint. Read what it is.

Is AOD-9604 licensed in the UK?

PeptGuru records AOD-9604's UK status as: Not licensed in the UK. None. UK status checked 14 November 2026. This is a record of regulation, not a recommendation. Read the UK status.

What does the research on AOD-9604 show?

PeptGuru records 4 research findings for AOD-9604: 2 from human trials and 2 from animal studies. Each finding has its own evidence grade, source and main limitation. Read the research findings.

What safety findings have been reported for AOD-9604?

2 safety findings are recorded, including: no IGF-1 or antibody signal; adverse-event reporting. Each is cited to its source. A short list does not mean a substance is safe. Read the safety findings.

Where are the sources for AOD-9604?

All 5 sources are listed in the references, each with a link to the original study or regulator document and its own source page on PeptGuru. See the references.

Review record and change log

Last reviewed
Evidence last reviewed
UK status checked
Reviewed by
PeptGuru editorial team
  • Correction · A finding based on an unidentifiable early-phase source was removed, as was an unsourced toxicology statement. The Phase IIb result is now cited to its 2005 conference record and a 2026 peer-reviewed review.
  • Regulatory update · UK status now cites a dated MHRA database check. WADA 2026 listing added (S2.2.3).

How findings are graded: the grading method. All changes.

  • TesamorelinTH9507

    Not licensed in the UK. Growth-hormone-releasing hormone analogue studied for visceral fat in HIV-associated lipodystrophy, in randomised trials.

    Growth hormone axisHuman trialsEvidence reviewed
    StrongNot licensed in the UK
  • CagrilintideAM833

    Not licensed in the UK. Investigational long-acting amylin analogue studied for weight management, alone and with semaglutide.

    Metabolic and incretinHuman trialsEvidence reviewed
    ModerateNot licensed in the UK
  • KisspeptinMetastin

    Natural reproductive hormone studied in UK trials for low sexual desire and IVF egg maturation. No UK marketing authorisation identified.

    Hormonal signallingHuman trialsEvidence reviewed
    LimitedNot licensed in the UK
  • Liraglutide

    Earlier-generation GLP-1 receptor agonist studied in type 2 diabetes and weight management. UK prescription-only medicine; licence status depends on the brand.

    Metabolic and incretinHuman trialsEvidence reviewed
    ModerateLicensed UK medicine

Compare AOD-9604 with Tesamorelin

Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.